Terns Pharmaceuticals, Inc. Common Stock
Here’s whether Terns Pharmaceuticals, Inc. Common Stock (TERN) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+6.39% over 10 days); strong 1-year return of +1386.8%; 3-month momentum positive (+43.8%). Concerns: RSI 79 — overbought, elevated pullback risk; declining volume on rally — weak conviction (0.35x 30d avg). Currently 0.5% off its 52-week high. Score: +4/7.
TERN is in a confirmed uptrend, trading above both its 50-day ($48.94) and 200-day ($27.52) moving averages. With an RSI of 78.6, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +1386.8% compares to +24.4% for SPY (beat the market by 1362.4%).